Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

732744

registered interest
date	26/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government, further to the Written Answer by the Parliamentary Under-Secretary of State, Department of Health, on 24 April (HC70973), when and how the Commission on Human Medicines "thoroughly review the data" on human papilloma virus (HPV) vaccine adverse reactions.
tabling member printed	The Countess of Mar
uin	HL182
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The Commission on Human Medicines (CHM) is the Government’s scientific advisory committee, from which the Medicines and Healthcare products Regulatory Agency (MHRA) seeks independent scientific advice.</p><p> </p><p>The CHM considered a thorough review of the safety of human papillomavirus (HPV) vaccine at its meeting on 16 July 2015. Prior to 2015, the CHM considered reviews of HPV vaccine at meetings in September 2012, September 2010, September 2009, June 2009 and February 2009. These reviews included evaluation of United Kingdom Yellow Card reports, analysis of data from the Clinical Practice Research Datalink (CPRD), published safety studies and safety data from other countries.</p><p>Most recently, the CHM considered the safety of HPV vaccine at its meeting on 15 October 2015. At this meeting, the MHRA sought advice from the CHM on the (Co)-Rapporteurs’ assessment reports prepared for the European Medicines Agency (EMA) review into reports of postural orthostatic tachycardia syndrome and complex regional pain syndrome following HPV vaccine, in order to inform the UK position in the review.</p><p><strong> </strong>As with all vaccines and medicines, the safety of HPV vaccine remains under continual review by the MHRA.</p> answering member printed Lord O'Shaughnessy question first answered 04/07/2017 16:04:46 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

732745

registered interest
date	26/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government whether, in the light of the significant increase in the number of cases of postural orthostatic tachycardia syndrome (POTS) reported as an adverse reaction to HPV vaccination since July 2015, they will ask the European Medicines Agency to review the safety signal.
tabling member printed	The Countess of Mar
uin	HL183
answer	answer is ministerial correction date of answer 03/07/2017 answer text <p>The European Medicines Agency (EMA) concluded a thorough review of reports of postural orthostatic tachycardia syndrome (POTS) following human papillomavirus (HPV) vaccine in November 2015, which found that the evidence did not support a causal association between HPV vaccination and POTS.</p><p> </p><p>As of 26 June 2017, the Medicines and Healthcare products Regulatory Agency (MHRA) has received 60 reports of POTS following HPV vaccine via the Yellow Card Scheme. More than three million girls have been vaccinated against HPV since 2008 across the United Kingdom, and the MHRA’s evaluation remains that the number of reports does not exceed what would be expected to occur in the absence of HPV vaccine and that the evidence does not suggest a causal association with the vaccine.</p><p> </p><p>The MHRA does not currently propose to ask the EMA to conduct a further review. As with the safety of all vaccines and medicines, this issue will remain under review.</p> answering member printed Lord O'Shaughnessy question first answered 03/07/2017 16:44:42 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

732746

registered interest
date	26/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government who advised the Commission on Human Medicines that the available evidence does not support a causal association between HPV vaccination and development of postural orthostatic tachycardia syndrome (POTS) or complex regional pain syndrome (CRPS) according to the Commission's minutes of 15–16 October 2015; and why this statement was made before the European Medicines Agency Scientific Advisory Group (SAG) reported on 21 October 2015.
tabling member printed	The Countess of Mar
uin	HL184
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The Commission on Human Medicines (CHM) is the Government’s scientific advisory committee, from which the Medicines and Healthcare products Regulatory Agency (MHRA) seeks independent scientific advice.</p><p> </p><p>Following a review of human papillomavirus (HPV) vaccine safety on 16 July 2015, the CHM advised the MHRA that the available evidence does not support a causal association between HPV vaccination and development of postural orthostatic tachycardia syndrome (POTS) or complex regional pain syndrome (CRPS), as well as other chronic illnesses. The public minutes of this meeting were made available online on 18 November 2015.</p><p> </p><p>At its meeting on 15 October 2015, the MHRA sought advice from the CHM on the (Co)-Rapporteurs’ assessment reports prepared for the European Medicines Agency (EMA) review into reports of POTS and CRPS following HPV vaccine, in order to inform the United Kingdom position in the review. The public minutes of this meeting were made available online on 21 December 2015.</p><p> </p><p>The CHM did not make a statement in October in advance of the EMA’s Scientific Advisory Group meeting. The CHM’s minutes were published on the above dates in line with usual practice and have informed the MHRA’s responses to enquiries about the safety of HPV vaccine.</p> answering member printed Lord O'Shaughnessy question first answered 04/07/2017 16:05:33 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

730989

registered interest
date	21/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	GP Surgeries: Opening Hours
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 3 February (HL4841), what was the average number of days that GP surgeries were open in the period 27–30 December 2016.
tabling member printed	Lord Birt
uin	HL14
answer	answer is ministerial correction date of answer 03/07/2017 answer text <p>The information requested is not held centrally.</p><p> </p><p>Core hours for general practices are defined in the General Medical Services and Personal Medical Services regulations, The National Health Service (General Medical Services Contracts and Personal Medical Services Agreements) (Amendment) Regulations 2016, SI 2016 No.875.</p><p> </p><p>Core hours are 8am – 6:30pm Monday to Friday, except Good Friday, Christmas Day and bank holidays.</p><p> </p><p>The 2015-16 GP Patient Survey showed that 74.6% of patients reported that their general practitioner surgery was open at convenient times and that 75.9% were satisfied with the hours that their surgery opened.</p><p> </p> answering member printed Lord O'Shaughnessy question first answered 03/07/2017 16:46:14 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2533 label Biography information for Lord Birt

731058

registered interest
date	21/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government when they intend to bring forward proposals for a consultation on social care.
tabling member printed	Baroness Lawrence of Clarendon
uin	HL66
answer	answer is ministerial correction date of answer 03/07/2017 answer text <p>The Government will work to address the challenges of social care for our ageing population, bringing forward proposals for consultation to build widespread support.</p><p> </p><p>We will provide further details on the next steps on social care in due course.</p><p><strong> </strong></p><p>The Government is committed to listening to people’s views on how to reform the social care system, to ensure it is sustainable for current and future generations and that the quality of care improves.</p> answering member printed Lord O'Shaughnessy question first answered 03/07/2017 11:42:12 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4290 label Biography information for Baroness Lawrence of Clarendon

731066

registered interest
date	21/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government whether they plan to convert EU Regulation 658/2014 into UK law; and, if so, which UK body will assume the role of the European Medicines Agency for the setting and charging of fees to UK-based marketing authorisation holders.
tabling member printed	Baroness Hayter of Kentish Town
uin	HL74
answer	answer is ministerial correction date of answer 29/06/2017 answer text <p>The Medicines and Healthcare products Regulatory Agency sets and charges fees for marketing authorisations in the United Kingdom which are granted nationally and not approved centrally by the European Medicines Agency. The extent to which European Medicines Agency procedures will apply in the UK after we have exited the European Union will be subject to negotiations. The Government will ensure that the UK’s full approval regime is ready and operational as soon as the UK has formally departed the EU.</p> answering member printed Lord O'Shaughnessy question first answered 29/06/2017 11:37:19 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4159 label Biography information for Baroness Hayter of Kentish Town

731067

registered interest
date	21/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government whether they plan to convert EU Regulation 536/2014 into UK law; and, if so, whether the UK will continue to notify the EU Clinical Trial Portal of applications for clinical trials for medicinal products for human use, and retain full access to the Portal.
tabling member printed	Baroness Hayter of Kentish Town
uin	HL75
answer	answer is ministerial correction date of answer 29/06/2017 answer text <p>The Prime Minister has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation. As part of exit negotiations the Government will discuss with the European Union and Member States how best to continue cooperation in the field of clinical trials, including access to the EU portal and database.</p><p> </p><p>The UK applied sustained pressure to successfully reform the current Clinical Trials Directive in the best interests of patients and business and is planning for the new Clinical Trials Regulation to be brought onto our statute book. The timing of the application date of the new regulation is yet to be determined by the European Commission.</p> answering member printed Lord O'Shaughnessy question first answered 29/06/2017 11:38:11 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4159 label Biography information for Baroness Hayter of Kentish Town

731068

registered interest
date	21/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government what change in funding in England for continued professional development for Registered Nurses took place in 2016/17; and what steps they are taking to address the situation.
tabling member printed	Baroness Watkins of Tavistock
uin	HL76
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The Department does not hold this information centrally.</p><p><strong> </strong></p><p>Responsibility for ongoing post registration Professional Development lies with individual employers.</p> answering member printed Lord O'Shaughnessy question first answered 04/07/2017 15:10:37 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4566 label Biography information for Baroness Watkins of Tavistock

731070

registered interest
date	21/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government when they intend to introduce legislation to reform professional healthcare regulation as proposed by the Law Commission in their report Regulation of Health and Social Care Professionals published in April 2014.
tabling member printed	Lord Warner
uin	HL78
answer	answer is ministerial correction date of answer 03/07/2017 answer text <p>The Government is considering options on how to take forward the reform and rationalisation of professional regulation.</p> answering member printed Lord O'Shaughnessy question first answered 03/07/2017 16:45:36 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1732 label Biography information for Lord Warner

731071

registered interest
date	21/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government whether they still intend to produce consultation proposals for the reform of social care by the end of 2017.
tabling member printed	Lord Warner
uin	HL79
answer	answer is ministerial correction date of answer 03/07/2017 answer text <p>The Government will work to address the challenges of social care for our ageing population, bringing forward proposals for consultation to build widespread support. We are committed to listening to people’s views on how to reform the social care system, to ensure it is sustainable for current and future generations and that the quality of care improves.</p><p> </p><p>As part of the overall package of reform, we will consult on detailed proposals which will include a capital floor and an absolute limit on the amount people can be asked to pay.</p><p> </p><p>We will provide further details on the next steps on social care in due course.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL80 question first answered 03/07/2017 16:45:15 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1732 label Biography information for Lord Warner